AlzChem's American Bet: Defense-Linked Growth and Specialty Chemicals Excellence

Q2 2026 results confirm strong momentum as U.S. site decision and EUR 100M financing pave the way for the next leg.

ACT.DE · Earnings Call · 2026-07-30

AlzChem Group delivered another strong half, with group revenue up 6% to €304 million and EBITDA up 14% to €64.5 million, as the Specialty Chemicals segment continued to flex its operating leverage. The segment alone grew revenue 10% and expanded EBITDA margin to ~30%, driven by human nutrition, defense-related applications, and custom manufacturing. The company confirmed its full-year guidance of ~€600 million sales and ~€126 million EBITDA, even as it noted some sales pull-forward from H2 into H1. “We have delivered a very successful first 6 months here with both revenue and earnings significantly exceeding the prior year level.” — Andreas Niedermaier · 2026-07-30

Defense-Linked U.S. Expansion: A Strategic Pivot

The most striking development this quarter is the formal site decision for a new nitroguanidine plant in Bushy Park, South Carolina. CEO Andreas Niedermaier emphasized: “With the site decision for Bushy Park in South Carolina, we have reached an important milestone in our nitroguanidine expansion for the U.S.” — Andreas Niedermaier · 2026-07-30 This project, which will be partially financed by the U.S. Department of Defense (DoD), is expected to contribute close to €100 million in revenue once fully ramped. It ties AlzChem directly into the global surge in defense spending, reflected in the appearance of Golden Dome and Iron Dome as top global keywords earlier this year—both are emblematic of the missile-defense programs that rely on propellants containing nitroguanidine. The company's defense related segment has been a key growth driver, and this U.S. footprint ensures supply-chain resilience for its customers. Financing is a non-issue. As CEO Niedermaier noted in Q&A:

So from our point of view, we are financed for our growth, no doubt about that because you may know that the U.S. project is already financed and will be financed by the DoD.
Andreas Niedermaier · 2026-07-30

The newly secured €100 million facility—€80 million drawn and €20 million committed—provides ample headroom; a portion was used to optimize existing debt. This positions the company to execute the expansion without dilutive actions.

Specialty Chemicals: The Growth Engine

The Specialty Chemicals segment remains the earnings engine, with EBITDA up 19% year-on-year. Alongside defense, Creavitalis (creatine) is soaring on the back of the Ehrmann dairy partnership and broader human-nutrition demand. The company is bringing new creatine capacity online; in the prior call, CEO Niedermaier confirmed: “So the additional capacity for creatine itself should be available for the second half of the year.” — Andreas Niedermaier, CEO · 2026-02-27 This quarter, CFO Andreas Losle added that pricing remains firm: “But you can be sure that the price did not drop in the second quarter. So I would say, more or less stable.” — Andreas Losle · 2026-07-30 The team is confident about absorbing the new volume given market tightness.

Operational Execution and Guidance

Operationally, the furnace refurbishment is progressing on schedule, with recommissioning in Q3. The one-off costs (~€10 million) are baked into guidance, and management expects Q3 revenue to be softer due to sales pull-forward, but Q4 to rebound with the nitroguanidine ramp. CFO Losle also reminded that customer grants for the German expansion will continue to support cash flow: “We still expect some more customer grants for our nitroguanidine expansion in the next year, which will increase our – or this year, which will increase our operating cash flow.” — Andreas Losle, CFO · 2026-02-27 With a robust balance sheet and clear strategic direction, AlzChem is well positioned to extend its growth trajectory into 2027 and beyond.